Agios Pharmaceuticals, Inc.
AGIO
$33.20
$0.611.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 44.75M | 20.75M | 19.97M | 12.88M | 12.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.75M | 20.75M | 19.97M | 12.88M | 12.46M |
| Cost of Revenue | 103.75M | 82.47M | 89.94M | 88.48M | 93.64M |
| Gross Profit | -59.01M | -61.72M | -69.97M | -75.60M | -81.19M |
| SG&A Expenses | 51.55M | 48.30M | 51.61M | 41.27M | 45.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.30M | 130.77M | 141.55M | 129.75M | 139.51M |
| Operating Income | -110.55M | -110.03M | -121.58M | -116.87M | -127.06M |
| Income Before Tax | -100.70M | -99.11M | -109.06M | -103.43M | -112.02M |
| Income Tax Expenses | -- | -- | -1.02M | -- | -- |
| Earnings from Continuing Operations | -100.70M | -99.11M | -108.04M | -103.43M | -112.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.70M | -99.11M | -108.04M | -103.43M | -112.02M |
| EBIT | -110.55M | -110.03M | -121.58M | -116.87M | -127.06M |
| EBITDA | -109.20M | -108.66M | -120.31M | -115.50M | -125.80M |
| EPS Basic | -1.69 | -1.69 | -1.85 | -1.78 | -1.93 |
| Normalized Basic EPS | -1.06 | -1.05 | -1.17 | -1.11 | -1.21 |
| EPS Diluted | -1.69 | -1.69 | -1.85 | -1.78 | -1.93 |
| Normalized Diluted EPS | -1.06 | -1.05 | -1.17 | -1.11 | -1.21 |
| Average Basic Shares Outstanding | 59.49M | 58.78M | 58.35M | 58.14M | 57.93M |
| Average Diluted Shares Outstanding | 59.49M | 58.78M | 58.35M | 58.14M | 57.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |